Obesity and Hormonal Contraception: Safety and Efficacy

Abstract

The biological capacity for pregnancy complicates the impact of obesity on the health and well-being of women. Consequently, the ability to prevent or plan pregnancies through the use of contraception is critical for obese women. Unfortunately, contraception is often forgotten or feared in women with chronic medical problems like obesity. This review addresses the safety and efficacy of hormonal contraceptive methods in obese women. Generally, the risks of pregnancy outweigh the risks of hormonal contraception in an obese woman, but obesity is a significant risk factor for thrombosis, which should be taken into account when recommending a combined hormonal method. Limited data suggest that the efficacy of some hormonal methods may be reduced in obese women.

Keywords

obesity - body mass index - efficacy - safety - unplanned pregnancy - venous thromboembolism

• References

• 1 Overweight and Obesity. U.S. Obesity trends (1985–2010). 2010: Available at: http://www.cdc.gov/obesity/data/trends.html . Accessed February 20, 2012
• 2 Boney CM, Verma A, Tucker R, Vohr BR. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics 2005; 115 (3) e290-e296
• 3 Catalano PM, Ehrenberg HM. The short- and long-term implications of maternal obesity on the mother and her offspring. BJOG 2006; 113 (10) 1126-1133
• 4 Whitaker RC. Predicting preschooler obesity at birth: the role of maternal obesity in early pregnancy. Pediatrics 2004; 114 (1) e29-e36
• 5 Marshall NE, Spong CY. Obesity, pregnancy complications and birth outcomes. Semin Reprod Med 2012; 30 (6) 463-469
• 6 Phelan S. Pregnancy: a “teachable moment” for weight control and obesity prevention. Am J Obstet Gynecol 2010; 202 (2) 135 , e1–e8
• 7 Centers for Disease Control and Prevention. U S. Medical Eligibility Criteria for Contraceptive Use, 2010. MMWR Recomm Rep 2010; 59 (RR-4) 1-86
• 8 Lidegaard O. Thrombotic diseases in young women and the influence of oral contraceptives. Am J Obstet Gynecol 1998; 179 (3 Pt 2) S62-S67
• 9 Lidegaard O, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism. A case-control study. Contraception 1998; 57 (5) 291-301
• 10 Control CFD. Medical eligibility criteria for contraceptive use. Morb Mortal Wkly Rep (MMWR): CDC; 2010
• 11 Heinemann LA, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. Contraception 2007; 75 (5) 328-336
• 12 Liu S, Rouleau J, Joseph KS , et al; Maternal Health Study Group of the Canadian Perinatal Surveillance System. Epidemiology of pregnancy-associated venous thromboembolism: a population-based study in Canada. J Obstet Gynaecol Can 2009; 31 (7) 611-620
• 13 Heit JA. The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis 2006; 21 (1) 23-29
• 14 Farmer RD, Lawrenson RA, Todd JC, Williams TJ, MacRae K. Oral contraceptives and venous thromboembolic disease. Analyses of the UK General Practice Research Database and the UK Mediplus database. Hum Reprod Update 1999; 5 (6) 688-706
• 15 Dinger JC, Heinemann LA, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007; 75 (5) 344-354
• 16 Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol 2007; 110 (3) 587-593
• 17 Pomp ER, le Cessie S, Rosendaal FR, Doggen CJ. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007; 139 (2) 289-296
• 18 Nightingale AL, Lawrenson RA, Simpson EL, Williams TJ, MacRae KD, Farmer RD. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care 2000; 5 (4) 265-274
• 19 Bonny AE, Secic M, Cromer B. Early weight gain related to later weight gain in adolescents on depot medroxyprogesterone acetate. Obstet Gynecol 2011; 117 (4) 793-797
• 20 Nilsson CG, Lähteenmäki P, Luukkainen T. Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD. Contraception 1980; 21 (3) 225-233
• 21 Shapiro S, Dinger J. Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies. J Fam Plann Reprod Health Care 2010; 36 (1) 33-38
• 22 Heinemann LA, Dinger JC, Assmann A, Minh TD. Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation “pill scare.”. Contraception 2010; 81 (5) 401-407
• 23 Dinger J, Assmann A, Möhner S, Minh TD. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J Fam Plann Reprod Health Care 2010; 36 (3) 123-129
• 24 Johnson JV, Lowell J, Badger GJ, Rosing J, Tchaikovski S, Cushman M. Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial. Obstet Gynecol 2008; 111 (2 Pt 1) 278-284
• 25 van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005; 72 (3) 168-174
• 26 Edelman AB, Cherala G, Stanczyk FZ. Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review. Contraception 2010; 82 (4) 314-323
• 27 Jensen JT, Burke AE, Barnhart KT, Tillotson C, Messerle-Forbes M, Peters D. Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis. Contraception 2008; 78 (6) 451-458
• 28 Grow DR. Metabolism of endogenous and exogenous reproductive hormones. Obstet Gynecol Clin North Am 2002; 29 (3) 425-436
• 29 Goebelsmann U, Mashchak CA, Mishell Jr DR. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol. Am J Obstet Gynecol 1985; 151 (7) 868-877
• 30 Klipping C, Duijkers I, Parke S, Mellinger U, Serrani M, Junge W. Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. Drugs R D 2011; 11 (2) 159-170
• 31 Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heinemann L. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997; 56 (3) 141-146
• 32 Lawrenson R, Farmer R. Venous thromboembolism and combined oral contraceptives: does the type of progestogen make a difference?. Contraception 2000; 62 (2, Suppl) 21S-28S ; discussion 37S–38S
• 33 Kongsayreepong R, Chutivongse S, George P , et al. A multicentre comparative study of serum lipids and apolipoproteins in long-term users of DMPA and a control group of IUD users. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 1993; 47 (2) 177-191
• 34 Godsland IF, Crook D, Simpson R , et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990; 323 (20) 1375-1381
• 35 Teichmann A. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel. Int J Fertil Menopausal Stud 1995; 40 (Suppl. 02) 98-104
• 36 Dilbaz B, Ozdegirmenci O, Caliskan E, Dilbaz S, Haberal A. Effect of etonogestrel implant on serum lipids, liver function tests and hemoglobin levels. Contraception 2010; 81 (6) 510-514
• 37 Kayikcioglu F, Gunes M, Ozdegirmenci O, Haberal A. Effects of levonorgestrel-releasing intrauterine system on glucose and lipid metabolism: a 1-year follow-up study. Contraception 2006; 73 (5) 528-531
• 38 Kahn HS, Curtis KM, Marchbanks PA. Effects of injectable or implantable progestin-only contraceptives on insulin-glucose metabolism and diabetes risk. Diabetes Care 2003; 26 (1) 216-225
• 39 Clarkson TB, Shively CA, Morgan TM, Koritnik DR, Adams MR, Kaplan JR. Oral contraceptives and coronary artery atherosclerosis of cynomolgus monkeys. Obstet Gynecol 1990; 75 (2) 217-222
• 40 Adams MR, Clarkson TB, Shively CA, Parks JS, Kaplan JR. Oral contraceptives, lipoproteins, and atherosclerosis. Am J Obstet Gynecol 1990; 163 (4 Pt 2) 1388-1393
• 41 Picardo CM, Nichols M, Edelman A, Jensen JT. Women's knowledge and sources of information on the risks and benefits of oral contraception. J Am Med Womens Assoc 2003; 58 (2) 112-116
• 42 Rosenberg M. Weight change with oral contraceptive use and during the menstrual cycle. Results of daily measurements. Contraception 1998; 58 (6) 345-349
• 43 Linné Y, Dye L, Barkeling B, Rössner S. Weight development over time in parous women—the SPAWN study—15 years follow-up. Int J Obes Relat Metab Disord 2003; 27 (12) 1516-1522
• 44 Blundell JE, Stubbs RJ, Golding C , et al. Resistance and susceptibility to weight gain: individual variability in response to a high-fat diet. Physiol Behav 2005; 86 (5) 614-622
• 45 Gallo MF, Grimes DA, Schulz KF, Helmerhorst FM. Combination estrogen-progestin contraceptives and body weight: systematic review of randomized controlled trials. Obstet Gynecol 2004; 103 (2) 359-373
• 46 Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2008; (4) CD003987
• 47 Lopez LM, Edelman A, Chen-Mok M, Trussell J, Helmerhorst FM. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev 2011; (4) CD008815
• 48 Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994; 49 (1) 56-72
• 49 Sivin I, el Mahgoub S, McCarthy T , et al. Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study. Contraception 1990; 42 (4) 361-378
• 50 Roepke TA. Oestrogen modulates hypothalamic control of energy homeostasis through multiple mechanisms. J Neuroendocrinol 2009; 21 (2) 141-150
• 51 Mayes JS, Watson GH. Direct effects of sex steroid hormones on adipose tissues and obesity. Obes Rev 2004; 5 (4) 197-216
• 52 Edelman A, Jensen JT, Bulechowsky M, Cameron J. Combined oral contraceptives and body weight: do oral contraceptives cause weight gain? A primate model. Hum Reprod 2011; 26 (2) 330-336
• 53 Society of Family Planning; Edelman A. Contraceptive considerations in obese women: release date 1 September 2009, SFP Guideline 2009. Contraception 2009; 80 (6) 583-590
• 54 Westhoff CL, Torgal AT, Mayeda ER, Shimoni N, Stanczyk FZ, Pike MC. Predictors of noncompliance in an oral contraceptive clinical trial. Contraception 2012; 85 (5) 465-469
• 55 Practice Committee of American Society for Reproductive Medicine. Obesity and reproduction: an educational bulletin. Fertil Steril 2008; 90 (5, Suppl) S21-S29
• 56 Lewis RA, Taylor D, Natavio MF, Melamed A, Felix J, Mishell Jr D. Effects of the levonorgestrel-releasing intrauterine system on cervical mucus quality and sperm penetrability. Contraception 2010; 82 (6) 491-496
• 57 Brunner Huber LR, Hogue CJ, Stein AD, Drews C, Zieman M. Body mass index and risk for oral contraceptive failure: a case-cohort study in South Carolina. Ann Epidemiol 2006; 16 (8) 637-643
• 58 Brunner Huber LR, Toth JL. Obesity and oral contraceptive failure: findings from the 2002 National Survey of Family Growth. Am J Epidemiol 2007; 166 (11) 1306-1311
• 59 Dinger J, Minh TD, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol 2011; 117 (1) 33-40
• 60 Dinger JC, Cronin M, Möhner S, Schellschmidt I, Minh TD, Westhoff C. Oral contraceptive effectiveness according to body mass index, weight, age, and other factors. Am J Obstet Gynecol 2009; 201 (3) 263 , e1–e9
• 61 Holt VL, Cushing-Haugen KL, Daling JR. Body weight and risk of oral contraceptive failure. Obstet Gynecol 2002; 99 (5 Pt 1) 820-827
• 62 Holt VL, Scholes D, Wicklund KG, Cushing-Haugen KL, Daling JR. Body mass index, weight, and oral contraceptive failure risk. Obstet Gynecol 2005; 105 (1) 46-52
• 63 Kaneshiro B, Edelman A, Carlson N, Nichols M, Jensen J. The relationship between body mass index and unintended pregnancy: results from the 2002 National Survey of Family Growth. Contraception 2008; 77 (4) 234-238
• 64 Segall-Gutierrez P, Taylor D, Liu X, Stanzcyk F, Azen S, Mishell Jr DR. Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously. Contraception 2010; 81 (6) 487-495
• 65 Edelman AB, Carlson NE, Cherala G , et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. Contraception 2009; 80 (2) 119-127
• 66 Mornar S, Chan LN, Mistretta E, Neustadt A, Martins A, Gilliam M. Pharmacokinetics of the etonogestrel contraceptive implant in obese women. Am J Obstet Gynecol 2012; 207 (2) 110.e1-6
• 67 Westhoff CL, Torgal AH, Mayeda ER, Pike MC, Stanczyk FZ. Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. Contraception 2010; 81 (6) 474-480
• 68 Glasier A, Cameron ST, Blithe D , et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception 2011; 84 (4) 363-367